相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study
Marie Auvray et al.
CLINICAL COLORECTAL CANCER (2020)
Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE)
Erna Forgo et al.
HISTOPATHOLOGY (2020)
A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer
Rachel Goodwin et al.
INVESTIGATIONAL NEW DRUGS (2020)
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
Filippo Pietrantonio et al.
CLINICAL CANCER RESEARCH (2020)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients?
Marco Puzzoni et al.
FUTURE ONCOLOGY (2020)
First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design
Thierry Andre et al.
FUTURE ONCOLOGY (2020)
Precision Therapy in RAS Mutant Colorectal Cancer
Rodrigo Dienstmann et al.
GASTROENTEROLOGY (2020)
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Chiara Cremolini et al.
LANCET ONCOLOGY (2020)
Systemic treatment for metastatic colorectal cancer in the era of precision medicine
Jaideep Sandhu et al.
JOURNAL OF SURGICAL ONCOLOGY (2019)
A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
Xiaofeng Chen et al.
ONCOLOGIST (2019)
Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer
Takeshi Suzuki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
Colin Weekes et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).
Shota Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update.
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12c inhibitor, in advanced solid tumors.
Marwan Fakih et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.
Salvatore Siena et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Clustered protocadherins methylation alterations in cancer
Ana Florencia Vega-Benedetti et al.
CLINICAL EPIGENETICS (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
526PDTRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study
Y Nakamura et al.
ANNALS OF ONCOLOGY (2019)
533PDBACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study
N B Mettu et al.
ANNALS OF ONCOLOGY (2019)
446PDPhase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours
R Govindan et al.
ANNALS OF ONCOLOGY (2019)
527PDTrastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial
J H Strickler et al.
ANNALS OF ONCOLOGY (2019)
LBA35Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification, cohort B) trial
A Sartore-Bianchi et al.
ANNALS OF ONCOLOGY (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients
Ilya G. Serebriiskii et al.
NATURE COMMUNICATIONS (2019)
Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer
Tadamichi Denda et al.
CANCER SCIENCE (2019)
Larotrectinib for the treatment of TRK fusion solid tumors
Theodore W. Laetsch et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2019)
Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer
Tomoyasu Yoshihiro et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2019)
GDNF and the RET Receptor in Cancer: New Insights and Therapeutic Potential
Lois M. Mulligan
FRONTIERS IN PHYSIOLOGY (2019)
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial
Chiara Cremolini et al.
JAMA ONCOLOGY (2019)
Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4
Jitske van den Bulk et al.
GENOME MEDICINE (2019)
Phase II study evaluating trifluridine/tipiracil plus bevacizumab and capecitabine plus bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis
K. Lesniewski-Kmak et al.
ANNALS OF ONCOLOGY (2018)
P-291The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress
P Ziranu et al.
ANNALS OF ONCOLOGY (2018)
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation
F. Morano et al.
ANNALS OF ONCOLOGY (2018)
Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins
Ed S. Kheder et al.
CLINICAL CANCER RESEARCH (2018)
A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer
Cristina Gravalos et al.
CLINICAL COLORECTAL CANCER (2018)
BRAF-mutant colorectal cancer, a different breed evolving
Eleonora Lai et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2018)
Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor
Antonio Fadda et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial
Jin Li et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
CANCER DISCOVERY (2018)
RET fusions observed in lung and colorectal cancers are sensitive to ponatinib
Joseph M. Gozgit et al.
Oncotarget (2018)
HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features
Jun Seok Park et al.
VIRCHOWS ARCHIV (2018)
NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines
Sun Young Kim et al.
JOURNAL OF CANCER (2018)
LBA18_PRDurable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
H-J J Lenz et al.
ANNALS OF ONCOLOGY (2018)
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
Beatrice Borelli et al.
ESMO OPEN (2018)
Global patterns and trends in colorectal cancer incidence and mortality
Melina Arnold et al.
GUT (2017)
CpG Island Methylator Phenotype-High Colorectal Cancers and Their Prognostic Implications and Relationships with the Serrated Neoplasia Pathway
Ye-Young Rhee et al.
GUT AND LIVER (2017)
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma
Fernando Rivera et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2017)
Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer
Yuji Miyamoto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
Rui-Hua Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Filippo Pietrantonio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE. Mutation
Jun Gong et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient
Massimo Milione et al.
ONCOTARGET (2017)
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Filippo Pietrantonio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer
Amir Mehrvarz Sarshekeh et al.
PLOS ONE (2017)
Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C
Mei Zeng et al.
CELL CHEMICAL BIOLOGY (2017)
A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer
Johanna C. Bendell et al.
CANCER INVESTIGATION (2017)
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies
N. Boeckx et al.
ANNALS OF ONCOLOGY (2017)
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation
M. A. Calegari et al.
BRITISH JOURNAL OF CANCER (2017)
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progressionaEuro
R. Obermannova et al.
ANNALS OF ONCOLOGY (2016)
Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target
Evgeny Yakirevich et al.
CLINICAL CANCER RESEARCH (2016)
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials
Susan D. Richman et al.
JOURNAL OF PATHOLOGY (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Marios Giannakis et al.
CELL REPORTS (2016)
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Alessio Amatu et al.
ESMO OPEN (2016)
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2015)
LBA-05Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2015)
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini et al.
LANCET ONCOLOGY (2015)
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li et al.
LANCET ONCOLOGY (2015)
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep Tabernero et al.
LANCET ONCOLOGY (2015)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Identification and characterization of RET fusions in advanced colorectal cancer
Anne-France Le Rolle et al.
ONCOTARGET (2015)
Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
Mihaela Angelova et al.
GENOME BIOLOGY (2015)
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations
Takayuki Yoshino et al.
INVESTIGATIONAL NEW DRUGS (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
J. Y. Douillard et al.
ANNALS OF ONCOLOGY (2014)
Replicative DNA polymerase mutations in cancer
Ellen Heitzer et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2014)
PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
Lee S. Schwartzberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers
Dara L. Aisner et al.
MOLECULAR CANCER RESEARCH (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
Elena Ardini et al.
MOLECULAR ONCOLOGY (2014)
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mutations in POLE and survival of colorectal cancer patients - link to disease stage and treatment
Albrecht Stenzinger et al.
CANCER MEDICINE (2014)
Frequency of HER-2 Positivity in Rectal Cancer and Prognosis
Lena-Christin Conradi et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
J. M. Juergensmeier et al.
BRITISH JOURNAL OF CANCER (2013)
Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens
Kimmie Ng et al.
CLINICAL CANCER RESEARCH (2013)
Predictive value of vascular endothelial growth factor overexpression in early relapse of colorectal cancer patients after curative resection
Hsiang-Lin Tsai et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
David Cunningham et al.
LANCET ONCOLOGY (2013)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
Jaafar Bennouna et al.
LANCET ONCOLOGY (2013)
Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas
Claire Palles et al.
NATURE GENETICS (2013)
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
C. Mao et al.
ANNALS OF ONCOLOGY (2012)
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
D. Santini et al.
ANNALS OF ONCOLOGY (2012)
MAP kinase genes and colon and rectal cancer
Martha L. Slattery et al.
CARCINOGENESIS (2012)
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies
Sandra F. Martins et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2011)
Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer
C. Mao et al.
BRITISH JOURNAL OF CANCER (2010)
Genome-wide association study for colorectal cancer identifies risk polymorphisms in German familial cases and implicates MAPK signalling pathways in disease susceptibility
Jesus Lascorz et al.
CARCINOGENESIS (2010)
Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome
E. Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer
Sara M. Johnson et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2010)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
Shuji Ogino et al.
GUT (2009)
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers
Eva Lin et al.
MOLECULAR CANCER RESEARCH (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers
Ludovic Barault et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
M. Frattini et al.
BRITISH JOURNAL OF CANCER (2007)
Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer
Eric Van Cutsem
CLINICAL COLORECTAL CANCER (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
DNA methylation in health, disease, and cancer
David S. Shames et al.
CURRENT MOLECULAR MEDICINE (2007)
The epidermal growth factor receptor pathway: A model for targeted therapy
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2006)
Angiogenesis in life, disease and medicine
P Carmeliet
NATURE (2005)
Perturbations of the AKT signaling pathway in human cancer
DA Altomare et al.
ONCOGENE (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma
F De Vita et al.
CANCER (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma
S Zheng et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2003)
Role of angiogenesis in tumor growth and metastasis
J Folkman
SEMINARS IN ONCOLOGY (2002)
VEGF-Trap: A VEGF blocker with potent antitumor effects
J Holash et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Trk receptor tyrosine kinases: A bridge between cancer and neural development
A Nakagawara
CANCER LETTERS (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
分享论文
